(Q37414033)

20 August 2017

1 reference

title

Idebenone: an emerging therapy for Friedreich ataxia (English)

1 reference

20 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Thomas Meier

1

1 reference

20 August 2017

Gunnar Buyse

series ordinal

2

1 reference

20 August 2017

publication date

1 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

256 Suppl 1

1 reference

20 August 2017

page(s)

25-30

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-009-1005-0

20 August 2017

exact match

0 references

cites work

Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-1005-0

Oxidative stress in patients with Friedreich ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-1005-0

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-1005-0

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-1005-0

Premarket notifications of new dietary ingredients--a ten-year review.

21 January 2018

1 reference

12 December 2020

Idebenone in patients with Friedreich ataxia

1 reference

12 December 2020

Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition.

1 reference

12 December 2020

Effects of 6-(omega-substituted alkyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinones and related compounds on mitochondrial succinate and reduced nicotinamide adenine dinucleotide oxidase systems

1 reference

12 December 2020

Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools

1 reference

12 December 2020

Safety, Tolerability, and Pharmacokinetics of High-Dose Idebenone in Patients With Friedreich Ataxia

1 reference

12 December 2020

Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up

1 reference

12 December 2020

Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up

1 reference

12 December 2020

The Interaction of Q Analogs, Particularly Hydroxydecyl Benzoquinone (Idebenone), with the Respiratory Complexes of Heart Mitochondria

1 reference

12 December 2020

Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study

1 reference

12 December 2020

Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism.

1 reference

12 December 2020

Inhibition of lipid peroxidation by a novel compound, idebenone (CV-2619).

1 reference

12 December 2020

Friedreich's ataxia: idebenone treatment in early stage patients

1 reference

12 December 2020

Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia

1 reference

12 December 2020

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

1 reference

12 December 2020

Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring

1 reference

12 December 2020

10.1007/S00415-009-1005-0

Identifiers

DOI

1 reference

20 August 2017

1 reference